Innovative AAGP ProtoKinetix is pursuing a patented anti-aging glycopeptide (AAGP) with potential to enhance cell survival across multiple therapeutic areas, presenting a cross-cutting sales opportunity to ophthalmology, dermatology, transplant services, and biomanufacturing.

Early-stage Monetization With revenue in the zero to low single digits and a modest funding round, there is an opportunity to position strategic partnerships, licensing, or milestone-based collaborations to accelerate clinical development and co-commercialization efforts.

Clinical Validation Path AAGP has undergone laboratory and multicenter testing across Europe and North America, with safety and efficacy signals reported; this creates a narrative for engaging translational research organizations, contract research partners, and specialty clinics seeking innovative cell-survival therapies.

Targeted Therapeutic Avenues Current focus areas include dry eye disease, cardiometabolic disorders, macular degeneration, and transplant support; these sectors offer near-term BD targets for collaboration, pilot programs, and research-sponsored trials.

Lean Partnerships Small team size (2–10 employees) and global patent-backed technology suggest scalable collaboration models with contract partners, CROs, academic groups, and biotech investors seeking low-overhead, high-potential ventures.